Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
about
Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues.Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment.Chromosomal instability and cytotoxicity induced by ribavirin: comparative analysis in cell lines with different drug-metabolizing profiles.Cytoplasmic rods and rings in ribavirin treatment.Cytoplasmic rods and rings in mycophenolic acid treatment.Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α.Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015Acyclonucleosides bearing coplanar arylethynyltriazole nucleobases: synthesis, structural analysis, and biological evaluationInosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus
P2860
Q39002714-80B1072C-FF3D-40B4-B471-20F9F7DA4918Q40053677-F5B8DC9E-3EAD-4775-A20D-5E76A8265046Q40203968-5FAB96CA-C4E4-4435-8315-447CFD5CA890Q41928089-8B3EBD10-E13A-4D58-8C36-C9183061C9E9Q47570080-14113E23-7010-4CAF-ABC6-C323CC98B176Q48175133-7D1A9B5E-1060-466F-BDED-8CD4CDCE4D3DQ48341677-810378F8-E8DF-4CE4-B08A-301630AF1E5DQ52620663-4BBB223F-9E45-4439-AA39-96E846177ED5Q52699072-A3A4BB6A-7E5C-406B-AE84-E26C47450775Q56889456-5F56D86C-56E4-4A19-BDA4-138DF1F40750Q58215325-5BBF24DD-A0DE-4669-8541-B2D0DF318832Q58682726-97F3DD7E-34BF-474A-9447-EC1F39FE5ED5
P2860
Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@en
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@nl
type
label
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@en
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@nl
prefLabel
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@en
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@nl
P2093
P2860
P356
P1433
P1476
Ribavirin revisited in the era ...... r hepatitis C virus infection.
@en
P2093
Fernando Tatsch
Ira M Jacobson
Jean-Michel Pawlotsky
Jordan J Feld
Mark S Sulkowski
P2860
P356
10.1111/LIV.13212
P5008
P577
2016-07-30T00:00:00Z
2017-01-01T00:00:00Z